Skip to main content

Receptor Occupancy (Flow Cytometry Assay) Characterization

 Receptor occupancy (RO) is a critical measurement in drug development, particularly for monoclonal antibodies like nivolumab. RO quantifies the proportion of target receptors (e.g., PD-1 on T-cells) occupied by the drug in vivo or in vitro, providing insights into the drug’s effective dose, pharmacodynamics (PD), and correlation with therapeutic efficacy.

Principle of Receptor Occupancy

Receptor occupancy measures the percentage of target receptors on cells that are bound by the therapeutic antibody at a given drug concentration. High receptor occupancy generally correlates with higher pharmacological activity, while an optimal RO is essential for therapeutic effect without excessive dosing.

In nivolumab’s case, RO would measure how effectively it binds PD-1 on T-cells or other immune cells, blocking PD-1/PD-L1 interactions and restoring T-cell activity.

Step-by-Step Procedure for Receptor Occupancy (Flow Cytometry Assay)

1. Materials and Reagents

  • Whole blood or peripheral blood mononuclear cells (PBMCs): Isolated from the patient or donor.
  • Fluorescently labeled nivolumab: To directly measure binding to PD-1.
  • Competing antibody (unlabeled anti-PD-1 or labeled anti-IgG): Used to measure free and occupied PD-1 receptors.
  • Fluorophore-conjugated anti-human PD-1 antibody: Recognizes both free and nivolumab-bound PD-1 receptors, or a separate secondary antibody to detect bound nivolumab.
  • Control antibodies: Isotype control and negative controls to account for non-specific binding.
  • Flow cytometer: For analyzing fluorescence-labeled cells and quantifying receptor occupancy.

2. Sample Preparation

  • Isolate PBMCs from whole blood if necessary or use whole blood samples directly.
  • Prepare cells for staining according to standard protocols, including any necessary cell fixation or blocking steps to minimize non-specific binding.

3. Staining for Receptor Occupancy

  • Determining Total PD-1:
    • Label one sample of cells with a fluorophore-conjugated anti-PD-1 antibody that can detect all PD-1 receptors (both nivolumab-bound and unbound).
  • Determining Free and Bound PD-1:
    • In a second sample, add nivolumab to saturate any free PD-1 receptors on cells. After incubation, use a labeled anti-PD-1 antibody that only detects unoccupied receptors to measure the “free” receptors.
    • Alternatively, add a competing fluorescent anti-IgG antibody that only binds to nivolumab-bound PD-1 to detect “occupied” receptors.

4. Incubation

  • Incubate the samples with antibodies at 4°C (to prevent internalization) or on ice, according to antibody manufacturer instructions. Typical incubation time is around 30–60 minutes, depending on the antibody binding kinetics.
  • Wash cells thoroughly to remove unbound antibodies and resuspend them in flow cytometry buffer.

5. Flow Cytometry Analysis

  • Run the samples on a flow cytometer to collect fluorescence data.
  • Use an appropriate gating strategy to identify the target cell population, such as T-cells, using markers like CD3 or CD8 alongside PD-1.
  • Measure the fluorescence intensity to determine the level of bound versus free PD-1 receptors on each cell population.

6. Calculating Receptor Occupancy

  • Calculate the receptor occupancy using the formula:

    Receptor Occupancy (%)=Total PD-1−Free PD-1Total PD-1×100\text{Receptor Occupancy (\%)} = \frac{\text{Total PD-1} - \text{Free PD-1}}{\text{Total PD-1}} \times 100

  • Where:

    • Total PD-1 is the fluorescence intensity from the sample where all PD-1 receptors are labeled.
    • Free PD-1 is the fluorescence intensity from the sample labeled with only unoccupied receptors.

7. Data Interpretation

  • High receptor occupancy (>80%) at therapeutic nivolumab concentrations generally indicates effective blockade of PD-1.
  • A dose-response relationship between nivolumab concentration and receptor occupancy can be established to guide dosing strategies.

Considerations

  • Specificity: Select antibodies with minimal cross-reactivity to ensure accurate measurement of both free and bound PD-1 receptors.
  • Isotype Controls: Include isotype controls to account for background fluorescence and confirm the specificity of the staining.
  • Temperature Control: Perform staining at 4°C or on ice to prevent internalization of PD-1 receptors during the incubation step, which could alter RO measurements.

Summary

Receptor occupancy analysis by flow cytometry provides valuable pharmacodynamic information, helping determine the dose needed to saturate PD-1 receptors on T-cells for nivolumab. By understanding the RO profile, researchers can better estimate dosing, understand efficacy thresholds, and optimize nivolumab’s therapeutic potential.

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more